Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)’s share price traded down 2.8% during mid-day trading on Tuesday . The company traded as low as $9.21 and last traded at $9.42, with a volume of 90,293 shares. The stock had previously closed at $9.69.

A number of equities analysts recently commented on AQXP shares. Jefferies Group raised their target price on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a report on Friday, August 5th. Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 21st. Needham & Company LLC started coverage on Aquinox Pharmaceuticals in a report on Thursday, May 12th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Zacks Investment Research cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $19.86.

The firm’s market cap is $154.74 million. The company’s 50 day moving average price is $8.09 and its 200-day moving average price is $8.46.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.22. Equities analysts predict that Aquinox Pharmaceuticals Inc. will post ($2.11) EPS for the current year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.